RxDoctor Payments Data

Navtej Brar, DO

Cardiovascular Disease · Phillipsburg, NJNPI 1255515292

Payments from drug & device makers

$2,011in general payments, 2019–2025

Across 102 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$632
  • AstraZeneca$398
  • Novartis$332
  • Pfizer$237
  • Edwards Lifesciences$145
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
  • plus $140 from 4 others

What the payments were for

  • Food & beverage$1,75287%
  • Education$25913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,011 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$427,590
Medicare patients
1,580
Services billed
6,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$371,122
XareltoRivaroxaban89$78,436
EntrestoSacubitril/Valsartan43$48,180
JardianceEmpagliflozin35$31,177
OzempicSemaglutide16$14,973
BrilintaTicagrelor13$8,029
Icosapent Ethyl11$5,822
Dabigatran EtexilateDabigatran Etexilate Mesylate21$5,735
Metoprolol Succinate436$5,451
Ezetimibe136$4,478
Atorvastatin Calcium421$4,202
Diltiazem 12hr ErDiltiazem Hcl16$2,986
Rosuvastatin Calcium157$2,405
Flecainide Acetate52$1,868
Losartan Potassium208$1,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$237$371,122405 claims
Johnson & JohnsonXarelto$23$78,43689 claims
NovartisEntresto$332$48,18043 claims
Boehringer IngelheimJardiance$15$31,17735 claims
AstraZenecaBrilinta$398$8,02913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Phillipsburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →